# Childhood-Onset Huntington’s Disease-Like Presentation of SCA17 with Intermediate Repeats, A Case Report

**Authors:** Meaghan Berns, Kelsey Jensen, Laura Speltz, Leonardo Brito Almeida

PMC · DOI: 10.1007/s12311-026-01979-3 · Cerebellum (London, England) · 2026-03-17

## TL;DR

A 14-year-old boy with SCA17 showed Huntington’s disease-like symptoms at a young age, despite having intermediate CAG/CAA repeats, challenging current understanding of the disease.

## Contribution

This is the first reported case of childhood-onset SCA17 with intermediate repeats, suggesting repeat length may not fully determine disease onset.

## Key findings

- A 14-year-old male with intermediate TBP gene repeats (43 and 37) presented with childhood-onset Huntington’s disease-like symptoms.
- The case challenges the assumption that intermediate CAG/CAA repeats only cause late-onset SCA17.
- Repeat expansion panels are emphasized as important for diagnosing complex movement disorders.

## Abstract

Objectives: In Spinocerebellar Ataxia type 17 (SCA17), penetrance is determined by repeat number of the CAG/CAA trinucleotide in the TATA-binding protein (TBP) gene. The intermediate range (41–48) exhibits only partial penetrance but may manifest a Huntington’s disease-like (HDL-4) syndrome with onset at age 50–60 years. We report a unique case of HDL-4 with childhood onset despite intermediate range repeats. Methods: This patient was evaluated at the University of Minnesota Movement Disorders Clinic. Standard Protocol Approvals, Registrations, and Patient Consents: Informed consent to disclose was obtained from the legal guardian of the subject of this report. Results: A 14-year-old male of Chinese descent presented with generalized dystonic and choreoathetoid movements since age 11 alongside motor delays, epilepsy, and speech, balance, and coordination dysfunction since infancy. Family history was limited given his adoptive status. Subsequent workup confirmed SCA17 with repeat numbers of 43 and 37 in the intermediate range. Discussion: This is the first case of intermediate range SCA17 of childhood-onset, emphasizing the evolving classification of intermediate vs. full penetrance while suggesting that the TBP repeat length may not be the sole determinant of disease onset and severity. It also highlights the importance of repeat expansion panels when investigating complex movement disorders.

## Linked entities

- **Genes:** TBP (TATA-box binding protein) [NCBI Gene 6908]
- **Diseases:** Spinocerebellar Ataxia type 17 (MONDO:0011781), Huntington’s disease (MONDO:0007739), epilepsy (MONDO:0005027)

## Full-text entities

- **Genes:** FXN (frataxin) [NCBI Gene 2395] {aka CyaY, FA, FARR, FRDA, X25}, ATXN2 (ataxin 2) [NCBI Gene 6311] {aka ATX2, SCA2, TNRC13}, PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) [NCBI Gene 5521] {aka B55BETA, PP2AB55BETA, PP2ABBETA, PP2APR55B, PP2APR55BETA, PR2AB55BETA}, ATXN1 (ataxin 1) [NCBI Gene 6310] {aka ATX1, D6S504E, SCA1}, GJB2 (gap junction protein beta 2) [NCBI Gene 2706] {aka BAPS, CX26, DFNA3, DFNA3A, DFNB1, DFNB1A}, CACNA1A (calcium voltage-gated channel subunit alpha1 A) [NCBI Gene 773] {aka APCA, BI, CACNL1A4, CAV2.1, DEE42, EA2}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, ATXN8 (ataxin 8) [NCBI Gene 724066], DPYD (dihydropyrimidine dehydrogenase) [NCBI Gene 1806] {aka DHP, DHPDHASE, DPD, DYPD}, ATXN10 (ataxin 10) [NCBI Gene 25814] {aka ATX10, E46L, HUMEEP, SCA10}, ATXN8OS (ATXN8 opposite strand lncRNA) [NCBI Gene 6315] {aka KLHL1AS, NCRNA00003, SCA8}, FGF14 (fibroblast growth factor 14) [NCBI Gene 2259] {aka FGF-14, FHF-4, FHF4, NYS4, SCA27, SCA27A}, FMR1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 2332] {aka FMRP, FRAXA, POF, POF1}, ATXN7 (ataxin 7) [NCBI Gene 6314] {aka ADCAII, OPCA3, SCA7, SGF73}, RFC1 (replication factor C subunit 1) [NCBI Gene 5981] {aka A1, CANVAS, MHCBFB, PO-GA, RECC1, RFC}, ATXN3 (ataxin 3) [NCBI Gene 4287] {aka AT3, ATX3, JOS, MJD, MJD1, SCA3}, TBP (TATA-box binding protein) [NCBI Gene 6908] {aka GTF2D, GTF2D1, HDL4, SCA17, TBP1, TFIID}, ATN1 (atrophin 1) [NCBI Gene 1822] {aka B37, CHEDDA, D12S755E, DRPLA, HRS, NOD}, STUB1 (STIP1 homology and U-box containing protein 1) [NCBI Gene 10273] {aka CHIP, HSPABP2, NY-CO-7, SCA48, SCAR16, SDCCAG7}
- **Diseases:** choreoathetosis (MESH:C567034), hyperkinetic (MESH:D006948), dysarthria (MESH:D004401), Huntington's Disease (MESH:D006816), cognitive delay (MESH:D003072), psychiatric symptoms (MESH:D001523), Huntington's disease-like (HDL-4) syndrome (MESH:C564616), Prader-Willi (MESH:D011218), epilepsy (MESH:D004827), ataxic (MESH:D001039), dystonia (MESH:D004421), sensorineural hearing loss (MESH:D006319), hypotonia (MESH:D009123), mesial temporal sclerosis (MESH:D000092223), developmental delay (MESH:D002658), hearing loss (MESH:D034381), dysmetria (MESH:D002524), anxiety (MESH:D001007), autosomal dominant disorder (MESH:D030342), seizures (MESH:D012640), non-syndromic hearing loss (MESH:C537845), cerebellar atrophy/degeneration (MESH:D013132), speech, balance, and coordination dysfunction (MESH:D013064), parkinsonism (MESH:D010302), motor delays (MESH:D006968), Movement Disorders (MESH:D009069), cerebellar atrophy (MESH:D002526), Ataxia (MESH:D001259), dementia (MESH:D003704), chorea (MESH:D002819)
- **Chemicals:** alcohol (MESH:D000438), midazolam (MESH:D008874), levetiracetam (MESH:D000077287), purine (MESH:C030985), pyrimidine (MESH:C030986), dopamine-blocking agents (-), fluoxetine (MESH:D005473), melatonin (MESH:D008550), diazepam (MESH:D003975)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12995942/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12995942/full.md

---
Source: https://tomesphere.com/paper/PMC12995942